These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 18342102)

  • 21. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
    Robert C; Faivre S; Raymond E; Armand JP; Escudier B
    Ann Intern Med; 2005 Aug; 143(4):313-4. PubMed ID: 16103482
    [No Abstract]   [Full Text] [Related]  

  • 22. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
    Deslandres M; Sibaud V; Chevreau C; Delord JP
    Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
    Berchem G; Dewilde S; Mahassen P
    Bull Soc Sci Med Grand Duche Luxemb; 2009; (1):7-9. PubMed ID: 19514172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
    Dasanu CA; Alexandrescu DT; Dutcher J
    South Med J; 2007 Mar; 100(3):328-30. PubMed ID: 17396743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
    Lipworth AD; Robert C; Zhu AX
    Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
    Lenihan DJ
    J Clin Oncol; 2008 Nov; 26(32):5154-5. PubMed ID: 18838702
    [No Abstract]   [Full Text] [Related]  

  • 27. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    Je Y; Schutz FA; Choueiri TK
    Lancet Oncol; 2009 Oct; 10(10):967-74. PubMed ID: 19767240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New drugs; sunitinib and sorafenib].
    van Bronswijk H; Dubois EA; Osanto S; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2888-90. PubMed ID: 18257434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
    Bukowski RM
    Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
    [No Abstract]   [Full Text] [Related]  

  • 30. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lacouture ME; Wu S; Robert C; Atkins MB; Kong HH; Guitart J; Garbe C; Hauschild A; Puzanov I; Alexandrescu DT; Anderson RT; Wood L; Dutcher JP
    Oncologist; 2008 Sep; 13(9):1001-11. PubMed ID: 18779536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
    Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
    Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
    [No Abstract]   [Full Text] [Related]  

  • 32. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
    Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
    [No Abstract]   [Full Text] [Related]  

  • 33. Adverse effects of anticancer agents that target the VEGF pathway.
    Chen HX; Cleck JN
    Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
    Hiles JJ; Kolesar JM
    Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sorafenib and sunitinib.
    Kim A; Balis FM; Widemann BC
    Oncologist; 2009 Aug; 14(8):800-5. PubMed ID: 19648603
    [No Abstract]   [Full Text] [Related]  

  • 36. Kidney cancer: Does hypothyroidism predict clinical outcome?
    Rini B
    Nat Rev Urol; 2011 Jan; 8(1):10-1. PubMed ID: 21116300
    [No Abstract]   [Full Text] [Related]  

  • 37. Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab.
    Ara M; Pastushenko E
    Actas Dermosifiliogr; 2014 Dec; 105(10):900-12. PubMed ID: 24766821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A; Sire M
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of vascular endothelial growth factor and multikinase inhibitor side effects.
    Wood LS
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():13-8. PubMed ID: 19948455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
    Pouessel D; Culine S
    Eur Urol; 2008 Feb; 53(2):376-81. PubMed ID: 17825982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.